GHENT, Belgium, May 20, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Biotech Value Fund Partners LP and Biotech Value Fund Inc.
Biotech Value Fund Partners LP and Biotech Value Fund Inc notified that they have dropped below the 5% threshold (from 5.23% to 4.93%) and now hold 2,417,991 Ablynx shares of the current 49,083,327 outstanding shares of Ablynx.
Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(R), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has more than 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin MosesCEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses@ablynx.com
Marieke VermeerschAssociate Director Investor Relationst: +32 (0)9 262 00 82m: +32 (0)479 49 06 03e: marieke.vermeersch@ablynx.comFollow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Nevillet: +44 203 709 5700e: ablynx@consilium-comms.com
pdf version of the press release http://hugin.info/137912/R/1787358/613665.pdf
Help employers find you! Check out all the jobs and post your resume.
